IQVIA Holdings Inc. has reported a significant transaction involving deferred shares by its director, Colleen A. Goggins. This transaction, which took place on November 5, 2026, is part of the company's ongoing efforts to align executive interests with shareholder value.

Goggins acquired 144 deferred shares at a price of $264.88 per share, bringing her total ownership to 5,441 shares. This move underscores IQVIA's commitment to transparency and good governance practices.

Background

IQVIA Holdings Inc. operates within the services-commercial physical and biological research sector, classified under SIC code 8731. The company is listed on the New York Stock Exchange under the ticker symbol IQV. IQVIA has undergone several name changes, previously known as Quintiles IMS Holdings, Inc. and Quintiles Transnational Holdings Inc.

What the Filing Says

The recent SEC filing, accession number 0001628280-26-072407, details Goggins' acquisition of the deferred shares. The filing states, "Each deferred share is convertible into one share of common stock of IQVIA Holdings Inc. upon settlement." The deferred shares become settleable under specific conditions, including a change in control of the company or the death of the reporting person.

Impact

This transaction may impact various stakeholders, including shareholders and other directors within the commercial physical and biological research industry. By acquiring additional shares, Goggins demonstrates confidence in the company's future performance, which may influence investor sentiment.

What's Next

The filing does not say what happens next.